Drug Trial Radar · NCT07186842
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
May 2030
Study completion May 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.
Conditions
- Advanced Solid Cancers
Interventions
BNT329Drug
Intravenous (IV) infusion
CA19-9-targeting monoclonal antibodyDrug
Monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B - Occurrence of dose-limiting toxicities within a participantTime frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.
- Parts A, B, and D - Occurrence of treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).
- Parts A, B, and D - Occurrence of dose interruptions, reductions, and discontinuation of BNT329 due to TEAEsTime frame: From the time of initiation of the first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).
- Part D - Objective response rate (ORR)Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
SCRI at HCA Health One
Denver, Colorado · Recruiting
Florida Cancer Specialists
Orlando, Florida · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Monash Health
Clayton, Australia · Recruiting
Austin Health
Heidelberg, Australia · Recruiting
St. Josef-Hospital im Katholischen Klinikum Bochum
Bochum, Germany · Recruiting
Klinikum der Universität München
München, Germany · Recruiting
Universitaetsklinikum Ulm
Ulm, Germany · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital San Pedro
Logroño, Spain · Recruiting
Hospital Universitario HM Sanchinarro - START Madrid CIOCC
Madrid, Spain · Recruiting
Hospital Universitario Quironsalud Madrid - NEXT Oncology
Pozuelo de Alarcón, Spain · Recruiting
St James´s University Hospital
Leeds, United Kingdom · Recruiting
Royal Free Hospital
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Northern Centre for Cancer Research
Newcastle upon Tyne, United Kingdom · Recruiting
The Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.